David J. Waxman

38.6k total citations · 12 hit papers
375 papers, 31.3k citations indexed

About

David J. Waxman is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, David J. Waxman has authored 375 papers receiving a total of 31.3k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Molecular Biology, 142 papers in Pharmacology and 122 papers in Oncology. Recurrent topics in David J. Waxman's work include Pharmacogenetics and Drug Metabolism (139 papers), Growth Hormone and Insulin-like Growth Factors (62 papers) and Drug Transport and Resistance Mechanisms (47 papers). David J. Waxman is often cited by papers focused on Pharmacogenetics and Drug Metabolism (139 papers), Growth Hormone and Insulin-like Growth Factors (62 papers) and Drug Transport and Resistance Mechanisms (47 papers). David J. Waxman collaborates with scholars based in United States, Canada and Germany. David J. Waxman's co-authors include Prabha A. Ram, F. Peter Guengerich, Thomas K. H. Chang, Frank J. Gonzalez, Jack L. Strominger, Soo-Hee Park, David R. Nelson, René Feyereisen, I. C. Gunsalus and Minor J. Coon and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David J. Waxman

370 papers receiving 30.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature

1996 2.4k citations David R. Nelson, René Feyereisen et al. profile →
The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and Nomenclature

1993 1.4k citations David R. Nelson, T. Kamataki et al. DNA and Cell Biology profile →
The P450 Superfamily: Update on New Sequences, Gene Mapping, and Recommended Nomenclature

1991 904 citations David R. Nelson, Minor J. Coon et al. DNA and Cell Biology profile →
Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression

1997 828 citations Richard J. Wilkins, David J. Waxman et al. profile →
Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

1986 668 citations F. Peter Guengerich, David J. Waxman et al. profile →
An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids

2001 607 citations David J. Waxman et al. profile →
P450 Gene Induction by Structurally Diverse Xenochemicals: Central Role of Nuclear Receptors CAR, PXR, and PPAR

1999 596 citations David J. Waxman profile →
Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes

2009 583 citations David J. Waxman et al. profile →
PENICILLIN-BINDING PROTEINS AND THE MECHANISM OF ACTION OF BETA-LACTAM ANTIBIOTICS

1983 546 citations David J. Waxman et al. profile →
Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes

1985 533 citations David J. Waxman, F. Peter Guengerich et al. profile →
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.

1993 457 citations David J. Waxman et al. PubMed profile →
Cytochrome P-450 hPCN3, a Novel Cytochrome P-450 IIIA Gene Product That Is Differentially Expressed in Adult Human Liver

1989 434 citations David J. Waxman, Frank J. Gonzalez et al. profile →

Peers

Countries citing papers authored by David J. Waxman

Since Specialization

Citations

This map shows the geographic impact of David J. Waxman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Waxman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Waxman more than expected).

Fields of papers citing papers by David J. Waxman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Waxman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Waxman. The network helps show where David J. Waxman may publish in the future.

Co-authorship network of co-authors of David J. Waxman

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Waxman. A scholar is included among the top collaborators of David J. Waxman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Waxman. David J. Waxman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: primary and secondary gene responses with links to disease progression 2024 ·Toxicological Sciences ·Ravi Sonkar, Hong Ma, David J. Waxman	4
2	Impact of Neonatal Activation of Nuclear Receptor CAR ( Nr 1 i 3) on Cyp2 Gene Expression in Adult Mouse Liver 2022 ·Toxicological Sciences ·Aram Shin, David J. Waxman	5
3	Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer 2022 ·Cancer Research Communications ·(unknown), (unknown), Darren Roblyer, David J. Waxman	7
4	Interplay Between GH-regulated, Sex-biased Liver Transcriptome and Hepatic Zonation Revealed by Single-Nucleus RNA Sequencing 2022 ·Endocrinology ·Christine N. Goldfarb, (unknown), (unknown), David J. Waxman	21
5	Constitutively Active STAT5b Feminizes Mouse Liver Gene Expression 2022 ·Endocrinology ·(unknown), Hong Ma, (unknown), André Sarmento‐Cabral, Mercedes del Río-Moreno, Rhonda D. Kineman, David J. Waxman	14
6	Harnessing natural variation to identify cis regulators of sex-biased gene expression in a multi-strain mouse liver model 2021 ·PLoS Genetics ·Bryan J. Matthews, Tisha Melia, David J. Waxman	5
7	Widespread Dysregulation of Long Noncoding Genes Associated With Fatty Acid Metabolism, Cell Division, and Immune Response Gene Networks in Xenobiotic-exposed Rat Liver 2020 ·Toxicological Sciences ·(unknown), David J. Waxman	9
8	Computational prediction of CTCF/cohesin-based intra-TAD loops that insulate chromatin contacts and gene expression in mouse liver 2018 ·eLife ·Bryan J. Matthews, David J. Waxman	44
9	Impact of Tumor Vascularity on Responsiveness to Antiangiogenesis in a Prostate Cancer Stem Cell-Derived Tumor Model 2013 ·Molecular Cancer Therapeutics ·Kexiong Zhang, David J. Waxman	18
10	VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity–Induced Tumor Regression 2012 ·Cancer Research ·Joshua C. Doloff, David J. Waxman	77
11	Antiangiogenesis Enhances Intratumoral Drug Retention 2011 ·Cancer Research ·Jie Ma, Chong-Sheng Chen, Todd Blute, David J. Waxman	42
12	Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib 2009 ·Clinical Cancer Research ·Jie Ma, David J. Waxman	36
13	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment 2008 ·Molecular Cancer Therapeutics ·Jie Ma, David J. Waxman	283
14	STAT5b Is Required for GH-Induced Liver Igf-I Gene Expression 2001 ·Endocrinology ·Helen W. Davey, Tao Xie, Michael J. McLachlan, Richard J. Wilkins, David J. Waxman, David R. Grattan	144
15	Serine Phosphorylation of GH-Activated Signal Transducer and Activator of Transcription 5a (STAT5a) and STAT5b: Impact on STAT5 Transcriptional Activity 2001 ·Molecular Endocrinology ·(unknown), Hiroko Yamashita, Hallgeir Rui, David J. Waxman	57
16	P450 enzyme expression patterns in the NCI human tumor cell line panel. 2001 ·PubMed ·(unknown), J M De Matias, Dominic A. Scudiero, Karen M. Hite, Anne Monks, Edward A. Sausville, David J. Waxman	77
17	Plasma Growth Hormone Pulse Activation of Hepatic JAK-STAT5 Signaling: Developmental Regulation and Role in Male-Specific Liver Gene Expression 2000 ·Endocrinology ·Hee Kyoung Choi, David J. Waxman	97
18	Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. 2000 ·PubMed ·Youssef Jounaïdi, David J. Waxman	52
19	The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and Nomenclature breakdown → 1993 ·DNA and Cell Biology ·David R. Nelson, T. Kamataki, David J. Waxman, F. Peter Guengerich, R.W. Estabrook, René Feyereisen, Frank J. Gonzalez, Minor J. Coon, I. C. Gunsalus, Osamu Gotoh, (unknown), (unknown)	1374
20	Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies 1993 ·Cancer Chemotherapy and Pharmacology ·E Frei, Sylvia A. Holden, René Gonin, David J. Waxman, Beverly A. Teicher	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact